Melissa M. Yoon
General Counsel at Ambry Genetics Corp.
Melissa M. Yoon active positions
| Companies | Position | Start | End |
|---|---|---|---|
Ambry Genetics Corp.
 Ambry Genetics Corp. Miscellaneous Commercial ServicesCommercial Services Ambry Genetics Corp. provides clinical genetic diagnostics and genetics software solutions. Its services include clinical diagnostics tests, forms, billing, order kits, patient resources about cancer, cardiology, billing information and research and collaboration services. The company was founded by Charles L.M. Dunlop and James Dunlop in 1999 and is headquartered in Aliso Viejo, CA. | General Counsel | - | - |
Career history of Melissa M. Yoon
Former positions of Melissa M. Yoon
| Companies | Position | Start | End |
|---|---|---|---|
| AKCEA THERAPEUTICS, INC. | Corporate Secretary | 2020-10-11 | - |
Statistics
International
| United States | 3 |
Operational
| General Counsel | 1 |
| Corporate Secretary | 1 |
Sectoral
| Commercial Services | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Ambry Genetics Corp.
Ambry Genetics Corp. Miscellaneous Commercial ServicesCommercial Services Ambry Genetics Corp. provides clinical genetic diagnostics and genetics software solutions. Its services include clinical diagnostics tests, forms, billing, order kits, patient resources about cancer, cardiology, billing information and research and collaboration services. The company was founded by Charles L.M. Dunlop and James Dunlop in 1999 and is headquartered in Aliso Viejo, CA. | Commercial Services |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Melissa M. Yoon
- Experience
